Creating value through innovation and impact
Avalo is a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
Investor contacts
Avalo Therapeutics
IR@avalotx.com
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com